Market Overview

Oppenheimer Reiterates Outperform Rating on Gilead Sciences Following Initial Idelalisib Ph.II Results

Share:

In a report published Monday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating and $61.00 price target on Gilead Sciences (NASDAQ: GILD).

In the report, Oppenheimer noted, “GILD reported initial ph.II results evaluating idelalisib (PI3K inhibitor) monotherapy in refractory indolent NHL. The results were within our expectations with idelalisib producing a 53.6% ORR, generally consistent with that seen in the prior ph.I single-agent study. We believe these results are compelling, given the study's heavily refractory patient population (~4 median prior therapies). Further, we believe this level of efficacy remains generally competitive with other investigational agents for NHL. Idelalisib's main area of uncertainty remains around its market potential, given the crowding NHL/CLL space. We currently model very conservative peak idelalisib sales of ~$700M in NHL/CLL, but see the potential for meaningful upside. We reiterate Outperform.”

Gilead Sciences closed on Friday at $52.23.

Latest Ratings for GILD

DateFirmActionFromTo
May 2020SunTrust Robinson HumphreyUpgradesSellHold
May 2020SVB LeerinkMaintainsMarket Perform
May 2020OppenheimerMaintainsOutperform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!

Posted-In: David Ferreiro OppenheimerAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
BKHMizuhoMaintains70.0
JOBAlliance Global PartnersUpgrades2.5
RARECanaccord GenuityMaintains91.0
TTDOppenheimerMaintains450.0
PYPLWedbushMaintains200.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com